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OBJECTIVE—The pathogenesis of type 1 diabetes has a strong
genetic component. Genome-wide association scans recently
identiﬁed novel susceptibility genes including the phosphatases
PTPN22 and PTPN2. We hypothesized that PTPN2 plays a direct
role in -cell demise and assessed PTPN2 expression in human
islets and rat primary and clonal -cells, besides evaluating its
role in cytokine-induced signaling and -cell apoptosis.
RESEARCH DESIGN AND METHODS—PTPN2 mRNA and
protein expression was evaluated by real-time PCR and Western
blot. Small interfering (si)RNAs were used to inhibit the expres-
sion of PTPN2 and downstream STAT1 in -cells, allowing the
assessment of cell death after cytokine treatment.
RESULTS—PTPN2 mRNA and protein are expressed in human
islets and rat -cells and upregulated by cytokines. Transfection
with PTPN2 siRNAs inhibited basal- and cytokine-induced
PTPN2 expression in rat -cells and dispersed human islets cells.
Decreased PTPN2 expression exacerbated interleukin (IL)-1
interferon (IFN)-–induced -cell apoptosis and turned IFN-
alone into a proapoptotic signal. Inhibition of PTPN2 ampliﬁed
IFN-–induced STAT1 phosphorylation, whereas double knock-
down of both PTPN2 and STAT1 protected -cells against
cytokine-induced apoptosis, suggesting that STAT1 hyperactiva-
tion is responsible for the aggravation of cytokine-induced -cell
death in PTPN2-deﬁcient cells.
CONCLUSIONS—We identiﬁed a functional role for the type 1
diabetes candidate gene PTPN2 in modulating IFN- signal
transduction at the -cell level. PTPN2 regulates cytokine-in-
duced apoptosis and may thereby contribute to the pathogenesis
of type 1 diabetes. Diabetes 58:1283–1291, 2009
T
ype 1 diabetes is a chronic autoimmune disease
with a strong genetic etiology. Genetic predispo-
sition to type 1 diabetes depends on a small
number of genes having large effects and a larger
number of genes having small effects (1). These genes
interact with putative environmental factors, which may
include viral infections, triggering insulitis and eventually
diabetes (2). Recent genome-wide association studies
have shown association between type 1 diabetes and four
chromosome regions, pointing to several new candidate
genes for the disease (3). Most of the newly and previously
identiﬁed genes are assumed to regulate immune function.
This contrasts with type 2 diabetes, where similar studies
indicate a major role for genes regulating -cell function
(4).
We have presently evaluated whether the recently iden-
tiﬁed candidate genes for type 1 diabetes (3,5) are ex-
pressed in pancreatic -cells and whether their expression
is modulated by proinﬂammatory cytokines. This was
done by examining our previous array analyses of cyto-
kine-treated or virus-infected rodent and human -cells/
pancreatic islets (6–10; complete information on these
arrays is available at the Beta Cell Gene Expression Bank
[11]) and new array analyses performed in our laboratory
using the new Affymetrix rat array Genechip 230.2.0 (un-
published data). This analysis identiﬁed -cell expression
of the candidate gene protein tyrosine phosphatase
(PTP)N2.
PTPN2 (also known as TC-PTP or PTP-S2) is a member
of the ﬁrst nontransmembrane (NT1) subfamily of PTPs.
PTPs are a superfamiliy of enzymes with opposite roles
compared with protein tyrosine kinases (12). PTPN2 is
expressed in immune cells, and its expression is modu-
lated by cell cycle, mitogenic agents, and cytokines (13).
PTPN2 exists as two isoforms generated from alternative
splicing: a major TC45 isoform (45 kDa) containing a
nuclear localization sequence and that shuttles between
the nucleus and the cytoplasm and a less abundant TC48
isoform (48 kDa) that is anchored to the endoplasmic
reticulum (13). Many targets have already been identiﬁed
for TC45, including Janus kinases (JAKs) and signal trans-
ducer and activator of transcription (STATs), p42/44 mito-
gen-activated protein kinase (MAPK) (extracellular signal–
related kinase [ERK]), epidermal growth factor receptor
(EGFR), and insulin receptor  (IR) (14–17). Several of
these pathways have been implicated in the control of
-cell physiology, survival, and expansion (18–20).
We have previously suggested that islet inﬂammation
and subsequent -cell death develops in the context of a
“dialogue” between the immune system and -cells (21).
Thus, -cells exposed to viral agents (6,22), or to endoge-
nous Toll-like receptor ligands (23), release cytokines and
chemokines that attract and activate macrophages, T-cells,
and B-cells. These immune cells will then trigger -cell
apoptosis via contact mediators such as Fas-FasL and/or
via secretion of proinﬂammatory cytokines such as inter-
feron (IFN)-, interleukin (IL)-1, and tumor necrosis
factor (TNF)- (21,24). IFN- has a key role in this
process. Thus, neither IL-1 nor TNF- alone induce
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cytokines with IFN- lead to 50% -cell death after 6–9
days (21,24). IFN- signal transduction involves activation
of the tyrosine kinases JAK1 and JAK2 that phosphorylate
STAT1, which then dimerizes and translocates to the
nucleus where it binds -activated sites of diverse genes
(21). Excessive activation of JAK/STAT signaling may lead
to cell death, and STAT1 transcriptional activity is regu-
lated by multiple negative feedback mechanisms, includ-
ing inhibition of JAKs by speciﬁc phosphatases and by the
suppressors of cytokine signaling and inhibition of STAT1
activity by protein inhibitor of activated STAT (PIAS)
proteins (25). -Cells from STAT1-deﬁcient mice
(STAT1
/) are protected against IL-1IFN-–induced
apoptosis, and STAT1
/ mice are more resistant to
diabetes induced by multiple low doses of streptozotocin
or after backcross into NOD mice (18,26). This protective
effect takes place at the -cell level, since islets from
STAT1
/, but not from wild-type mice, prevent diabetes
when transplanted into wild-type mice subsequently
treated with multiple low doses of streptozotocin (27).
However, it still remains unclear whether modulation of
phosphatases modiﬁes IFN-–induced -cell apoptosis.
We presently report that PTPN2 is regulated by the
cytokines IL-1, IFN-, and TNF- in rodent and human
pancreatic islet cells. Importantly, small interfering
(si)RNA-mediated PTPN2 knockdown increases STAT1
activation and aggravates cytokine-induced -cell apopto-
sis in a STAT1-dependent manner. These observations
indicate that one of the new candidate genes for type 1
diabetes may act at the immune and -cell level, exacer-
bating cytokine-induced -cell apoptosis under inﬂamma-
tory conditions.
RESEARCH DESIGN AND METHODS
Culture of primary ﬂuorescence-activated cell–sorted rat -cells, hu-
man islets, and INS-1E cells. Male Wistar rats (Charles River Laboratories,
Brussels, Belgium) were housed and used according to the guidelines of the
Belgian Regulations for Animal Care. Islets were isolated by collagenase
digestion and handpicked under a stereomicroscope. -Cells were puriﬁed by
autoﬂuorescence-activated cell sorting (FACSAria; BD Bioscience, San Jose,
CA) (28,29). The preparations contained 90.4  3.2% -cells (n  4). -Cells
were cultured for 2 days in Ham’s F-10 medium containing 10 mmol/l glucose,
2 mmol/l glutaMAX, 50 mol/l 3-isobutyl-1-methylxanthine, 5% fetal bovine
serum (FBS), 0.5% charcoal-absorbed BSA (Boehringer, Indianapolis, IN), 50
units/ml penicillin, and 50 g/ml streptomycin (29,30). During cytokine
exposure, cells were cultured in the same medium but without serum.
Human islets were isolated from 11 nondiabetic organ donors (age 63  5
years; BMI 25.1  0.8 kg/m
2) in Pisa, Italy, with the approval of the local ethics
committee. Islets were isolated by enzymatic digestion and density-gradient
puriﬁcation (31) and cultured in M199 medium containing 5.5 mmol/l glucose.
Their functional status was determined using glucose-stimulated insulin
release and was 2.8  0.4 (expressed as stimulation index). The human islets
were shipped to Brussels within 1–5 days of isolation. After overnight
recovery in Ham’s F-10 containing 6.1 mmol/l glucose, 10% FBS, 2 mmol/l
GlutaMAX, 50 mol/l 3-isobutyl-1-methylxanthine, 1% BSA, 50 units/ml peni-
cillin, and 50 g/ml streptomycin, islets were exposed to cytokines in the same
medium without FBS for 2 days. The percentage of -cells, examined in the 11
dispersed islet preparations by staining with anti-insulin antibody (1:1,000;
Sigma, Bornem, Belgium) and donkey anti-mouse IgG rhodamine (1:200;
Lucron Bioproducts, De Pinte, Belgium), was 49  5%.
The rat insulin-producing INS-1E cell line (a gift from Dr. C. Wollheim,
Centre Medical Universitaire, Geneva, Switzerland) was cultured as previ-
ously described (32,33).
RNA interference. The siRNAs used in this study are listed in Supplementary
Table A1 (available in an online-only appendix at http://diabetes.
diabetesjournals.org/cgi/content/full/db08-1510/DC1). The best settings for the
transfection of siRNAs in INS-1E cells, primary ﬂuorescence-activated cell–
sorted rat -cells, and dispersed human islets were established by using a
ﬂuorescein isothiocyanate (FITC)-conjugated siRNA (siGLO Green Transfec-
tion Indicator, Thermo Scientiﬁc). Different transfection methods were tested,
including electroporation, and several lipid reagents. Among those, Dharma-
FECT 1 (Thermo Scientiﬁc) was selected for its high transfection efﬁciency,
namely 95  2.7% in INS-1E cells and 80.7  5.6% in primary rat -cells. No cell
toxicity was observed with this transfection method (% cell death: 9.4  1.7%
after transfection vs. 8.4  2.2% in control for INS-1E cells and 9.8  1.3% after
transfection vs. 7.4  1.7% in control for primary rat -cells). Cells were
cultured in antibiotic-free medium for at least 24 h before transfection. For
transfection, the siRNA and the DharmaFECT were diluted separately in
OptiMEM medium and incubated at room temperature for 5 min. Lipid-siRNA
complexes were then formed at room temperature for 20 min in a proportion
of 0.75, 1.25, and 1.75 l DharmaFECT to 150 nmol/l of siRNA for INS-1E cells,
primary -cells, and dispersed human islets, respectively. The complexes
were diluted ﬁve times in antibiotic-free medium and added to the cells at a
ﬁnal concentration of 30 nmol/l siRNA (except when indicated otherwise) for
overnight transfection. The concentration of 30 nmol/l was selected after
dose-response studies (data not shown). Afterward, cells were cultured for a
48-h recovery period and subsequently exposed to cytokines.
Cell treatment and nitric oxide measurement. The following cytokine
concentrations were used, based on previous dose-response experiments
(10,24,33): recombinant human IL-1 (speciﬁc activity 1.8 	 10
7 units/mg; a
gift from C.W. Reinolds, National Cancer Institute, Bethesda, MD) at 10, 50, or
100 units/ml as indicated; recombinant murine TNF- (speciﬁc activity: 2 	
10
8 units/mg; Innogenetics, Gent, Belgium) at 1,000 units/ml; and recombinant
rat and human IFN- (speciﬁc activity: 2 	 10
7 units/mg; R&D Systems,
Abingdon, U.K.) at 100 and 1,000 units/ml for rat cells and human islets,
respectively. When cells were treated with cytokines, culture supernatants
were collected for nitrite determination (nitrite is a stable product of nitric
oxide [NO] oxidation) at OD
540 nm using the Griess method (34). Palmitate
(sodium salt, Sigma) was dissolved in 90% ethanol, heated to 60°C, and used
at a ﬁnal concentration of 0.5 mmol/l in medium containing 1% BSA (35). The
SERCA blocker CPA (Sigma) was dissolved in DMSO and used at a concen-
tration of 25 mol/l.
Assessment of cell viability. The percentage of viable, apoptotic, and
necrotic cells was determined after a 15-min incubation with the DNA-binding
dyes propidium iodide (PI, 5 g/ml; Sigma) and Hoechst 33342 (HO, 5 g/ml;
Sigma) (10,29,36). A minimum of 500 cells was counted in each experimental
condition. Viability was evaluated by two independent observers, one of them
being unaware of sample identity. The agreement between ﬁndings obtained
by the two observers was 
90%. Results are expressed as percent apoptosis,
calculated as number of apoptotic cells/total number of cells 	 100. In some
experiments, apoptosis was conﬁrmed using the Cell Death Detection
ELISAplus kit (Roche Diagnostics, Vilvoorde, Belgium), which detects cyto-
plasmic fragmented DNA.
mRNA extraction and real-time PCR. Poly(A)
 mRNA was isolated from
INS-1E cells, rat primary -cells, and human islets using the Dynabeads mRNA
DIRECT kit (Invitrogen) and reverse transcribed as previously described
(10,29,37). The real-time PCR ampliﬁcation reaction was done as described
(29,37), using SYBR Green and compared with a standard curve (38).
Expression values were corrected for the housekeeping gene glyceraldehyde-
3-phosphate dehydrogenase (GAPDH). IL-1 alone does not modify GAPDH
expression, whereas exposure to IL-1IFN- reduces its expression
according to cell death in INS-1E cells (Supplementary Fig. A1 and 7,10). The
primers used in this study are detailed in Supplementary Table A2 (online
appendix).
Western blot analysis. Cells were washed with cold PBS and lysed with
either Laemmli buffer or phospho lysis buffer (the compositions of the buffers
are provided in Supplementary Table A3). Lysates were then resolved by
8–10% SDS-PAGE and transferred to a nitrocellulose membrane. The antibod-
ies used in this study are listed in Supplementary Table A4. Immunoreactive
bands were revealed using the SuperSignal West Femto chemiluminescent
substrate (Thermo Scientiﬁc), detected using a LAS-3000 charge-coupled
device camera and quantiﬁed with the Aida Analysis software (Fujiﬁlm).
Immunoﬂuorescence. INS-1E cells were seeded onto glass coverslips and
treated as indicated. Cells were washed with cold PBS, ﬁxed for 10 min in
100% methanol at 20°C, washed three times with PBS, quenched 5 min in
PBS/0.1% sodium borohydride, washed twice with PBS, and incubated for 5
min in PBS containing 0.2% Triton X-100 (PBST). After a 1-h blocking with 5%
normal goat serum in PBST, cells were incubated overnight with PTPN2
antibodies (0.7 g/ml) in PBST/0.5% normal goat serum (Supplementary Table
A4). Cells were washed three times with PBST, and FITC-conjugated goat
anti-mouse antibodies (Lucron Bioproducts) were applied for2ha t1:200 in
PBST. After two washes with PBST, nuclei were counterstained with Hoechst
33342 (HO) for 5 min and washed three times with PBS. Coverslips were
mounted in mounting medium (Dakocytomation), and immunoﬂuorescence
was visualized on a Zeiss microscope.
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performed by two-tailed paired Student’s t test or by ANOVA followed by
Student’s t test with Bonferroni correction. A P value 0.05 was considered
statistically signiﬁcant.
RESULTS
Cytokines upregulate PTPN2 mRNA and protein ex-
pression in primary rat -cells, human islets, and
INS-1E cells. We ﬁrst evaluated the expression of PTPN2
mRNA (both TC45 and TC48 isoforms) in primary ﬂuores-
cence-activated cell–sorted rat -cells, human islets, and
rat insulin–producing INS-1E cells and tested whether
cytokine treatment would affect its expression. PTPN2
mRNA was expressed in untreated primary rat -cells and
human islets cells, and IL-1IFN- exposure upregu-
lated its expression by 9.6-fold (rat -cells) and 2.2-fold
(human islets) after 24 and 48 h, respectively (Fig. 1A and
B). A time course of IL-1IFN- treatment in INS-1E
cells indicated that PTPN2 mRNA was already induced
after 2 h, increasing progressively up to 24 h (Fig. 1C). We
then conﬁrmed by Western blot that PTPN2 was upregu-
lated by two- and threefold, respectively, in human islets
and INS-1E cells after IL-1IFN- treatment (Fig. 1D
and E and Fig. 3B and C). In accordance with previous
reports (13), we observed TC45 (arrow, Figs. 1D and 3B)
to be the major PTPN2 isoform expressed in -cells, with
TC48 being poorly expressed (Fig. 1D and 3B). In contrast,
the expression of PTPN22 (another phosphatase associ-
ated with type 1 diabetes risk; 39) was only present in
samples from rat spleen and lymph nodes (used as positive
controls), whereas no or marginal PTPN22 expression was
observed in primary -cells, human islets, and INS-1E
cells. The expression of PTPN22 was not modiﬁed by
cytokines (Supplementary Fig. A2 in the online appendix).
PTPN2 subcellular distribution. PTPN2 was mainly
located in the nucleus under unstimulated conditions (Fig.
2, left panels). However, a 15-min treatment with IFN-
alone or in combination with IL-1 or TNF- resulted in
redistribution of the protein between the cytoplasm and
the nucleus (Fig. 2, middle and right panels).
siRNA targeting PTPN2 inhibits basal and cytokine-
induced PTPN2 expression and exacerbates cyto-
kine-induced apoptosis in INS-1E cells, primary rat
-cells, and dispersed human islets. We next examined
the role of PTPN2 in -cells. To this end, INS-1E cells were
left untransfected, transfected with an irrelevant control
siRNA (siCtrl), or with an siRNA targeting both PTPN2
isoforms (siPTPN2). Cells were then left untreated, or
treated for 24 h with IL-1, IFN-, TNF-, or with the
combination of IL-1IFN- or TNF-IFN-. PTPN2
mRNA expression was signiﬁcantly upregulated after
IL-1 and IL-1IFN- treatment in untransfected and
siCtrl-transfected INS-1E cells (Fig. 3A). The expression of
PTPN2 proteins was increased by all cytokines tested,
alone or in combination, in both untransfected and siCtrl-
transfected cells (Fig. 3B and C), suggesting that PTPN2
expression is regulated at both transcriptional and post-
transcriptional levels. Transfection with PTPN2 siRNA
potently inhibited basal and cytokine-induced PTPN2 ex-
pression at the mRNA and protein level (Fig. 3A–C). We
then evaluated whether siRNA-mediated PTPN2 inhibition
affects cytokine-induced apoptosis in INS-1E cells. As
expected, a 24-h treatment with IL-1IFN- or TNF-
IFN- induced apoptosis in untransfected and siCtrl-trans-
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FIG. 1. Cytokines upregulate PTPN2 expression in primary ﬂuorescence-activated cell–sorted rat -cells, human islets, and INS-1E cells. A: Rat
-cells were cultured for 2 days and subsequently left untreated or treated with the combination of IL-1 (10 units/ml)  IFN- (100 units/ml)
for 24 h. B, D, and E: Hand-picked human islets were cultured overnight and then left untreated or exposed to IL-1 (50 units/ml)  IFN- (1,000
units/ml) for 48 h. C: INS-1E cells were left untreated or treated with IL-1 (10 units/ml)  IFN- (100 units/ml) for 2, 6, and 24 h as indicated.
A–C: PTPN2 mRNA expression was assayed by RT-PCR and normalized for the housekeeping gene GAPDH. D: PTPN2 and -tubulin expression
in human islets were evaluated by Western blot. E: Mean optical density measurements of PTPN2 Western blots corrected for protein loading by
-tubulin (representative ﬁgure in D). Results are means  SE of three to ﬁve independent experiments. *P < 0.05, **P < 0.01, and ***P < 0.001
vs. untreated cells by Student’s t test. NS, nonstimulated (untreated).
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4A; of note, the necrotic component was 2% under all
experimental conditions tested; data not shown). The
inhibition of PTPN2 exacerbated -cell apoptosis after
exposure to both IL-1IFN- and TNF-IFN-
treatments. Importantly, PTPN2 inhibition also rendered
IFN- treatment toxic to the cells, whereas this cytokine
alone failed to induce apoptosis in both control counter-
parts (Fig. 4A). These results were conﬁrmed using a
second method to evaluate apoptosis, namely quantiﬁca-
tion of cytoplasmic fragmented DNA (Fig. 4B), and also
with a second siRNA targeting PTPN2 (see below). The
increased apoptosis in cytokine-treated PTPN2-deﬁcient
INS-1E was not accompanied by a more severe decrease in
Ins1 and Ins2 mRNA contents in these cells (Supplemen-
tary Fig. A3) and could not be explained by a higher
release of NO, since nitrite was similarly produced by
untransfected, siCtrl-, and siPTPN2-transfected cells after
IL-1, IL-1IFN-, and TNF-IFN- treatments (Fig.
4C). Blocking PTPN2 using siRNA also augmented IFN-–,
IL-1IFN-–, and TNF-IFN-–induced apoptosis in
primary rat -cells (Fig. 4D). Similar observations were
made in dispersed human islet cells, in which siRNA-
mediated PTPN2 inhibition exacerbated IL-1IFN-–
induced cell death by 30–38% (Fig. 4E and F). This was
again independent of NO production (data not shown).
This effect seems to be speciﬁc for cytokines, since PTPN2
inhibition did not increase -cell apoptosis in response to
palmitate, high glucose, or the SERCA blocker CPA (Sup-
plementary Fig. A4).
PTPN2 inhibition increases IFN-–induced STAT1
and STAT3 phosphorylation. Taking into account that
STAT1 is a substrate of PTPN2 in other cell types (13) and
that it is an important mediator of cytokine-induced -cell
apoptosis (18), we next examined the effect of PTPN2
inhibition on the kinetics and magnitude of IFN-–induced
STAT1 phosphorylation. STAT1 phosphorylation was
highly induced after 15 min of IFN- treatment in both
untransfected and siCtrl-transfected controls, slowly de-
creasing between 2 and 24 h (Fig. 5A and B). However,
IFN-–induced STAT1 phosphorylation was markedly en-
hanced in cells lacking PTPN2, reaching a peak at 1–2 h
and slowly decreasing afterward (Fig. 5A and B). We
conﬁrmed that the increased STAT1 phosphorylation in
PTPN2-deﬁcient cells was not due to an augmentation of
total STAT1 content in these cells (Fig. 5A). Comparable
results were observed for STAT3, another target of PTPN2
phosphatase activity, with clearly increased STAT3 phos-
phorylation in PTPN2-deﬁcient cells (Fig. 5A and C). These
data demonstrate that the phosphatase PTPN2 is a major
modulator of IFN-–induced STAT1 and STAT3 activity in
-cells. We also evaluated the p42/44 MAPK (ERK), EGFR,
and IR activation pathways, previously described as
PTPN2 targets in other cell types (14,16,40). Neither ERK
nor EGFR signaling pathways were affected after PTPN2
inhibition in INS-1E cells (Supplementary Fig. A5). On the
other hand, there was an increase in IR phosphorylation
after 30 min of cytokine treatment in PTPN2-inhibited
INS-1E cells that lasted until 14 h (Supplementary Fig. A5).
Double knockdown of PTPN2 and STAT1 protects
INS-1E cells against cytokine-induced apoptosis. To
evaluate the role of STAT1 in the exacerbation of cytokine-
induced -cell apoptosis observed after PTPN2 inhibition,
we additionally interfered with STAT1 in a double knock-
down approach. We ﬁrst conﬁrmed by Western blot that
both PTPN2 and STAT1 siRNAs adequately inhibited their
respective targets without affecting the expression of the
other protein and also that the double transfection of
PTPN2 and STAT1 siRNAs potently inhibited both target
proteins (Fig. 6A). As previously shown (Fig. 4), IL-1
IFN- or TNF-IFN- induced apoptosis to a similar
degree in both control conditions, and PTPN2 inhibition
exacerbated cytokine-induced apoptosis, also rendering
treatment with IFN- alone toxic to the cells (Fig. 6B).
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IFN-- and TNF-IFN-–induced apoptosis (by 56 and
67%, respectively). STAT1 knockdown abrogated the pro-
apoptotic effect of PTPN2 inhibition in cells exposed to
IFN- or to combinations of cytokines (Fig. 6B). These
results were conﬁrmed using a second siRNA targeting
PTPN2 expression (Supplementary Fig. A6) and suggest
that increased STAT1 activity contributes to the aggrava-
tion of cytokine-induced apoptosis in PTPN2-deﬁcient
-cells.
DISCUSSION
We presently show that the phosphatase PTPN2 is ex-
pressed in human islets and rat primary and immortal
-cells and that its expression is regulated by the pro-
inﬂammatory cytokines IL-1, IFN-, and TNF- in these
cells. PTPN2 was ﬁrst identiﬁed in humans as a T-cell PTP
(41) with two spliced variants, namely TC45 and TC48
(13,42). In rat -cells and human islets, the TC45 isoform is
by far the most prevalent (Fig. 1D and 3B), and it is able to
shuttle between the nucleus and the cytoplasm after
cytokine exposure (Fig. 2). This change in subcellular
location of PTPN2 has been shown previously in other cell
types (14,16) and allows the phosphatase to target numer-
ous cellular substrates, including cytoplasmic JAK ty-
rosine kinases, EGFR, the IR and nuclear STAT1, STAT3,
STAT5, and STAT6 (43,44). Because of its modulatory role
in a wide variety of signaling pathways, perturbations in
PTPN2 expression are associated with diverse pathogenic
processes, including ABC-like diffuse large B-cell lympho-
mas (45), inﬂammation-associated tumorigenesis (44), and
several autoimmune disorders (see below).
PTPN2 inhibition in -cells results in an early and more
intense STAT1 and STAT3 activation after IFN- treat-
ment, suggesting that this phosphatase plays an important
role in the dephosphorylation and consequent inactivation
of these transcription factors in -cells. This early regula-
tion of IFN-–induced STAT1 activation seems to be
critical for the subsequent triggering of -cell apoptosis,
since PTPN2-deﬁcient -cells show an aggravation of
cytokine-induced apoptosis, which is reverted by the com-
bined inhibition of PTPN2 and STAT1. Importantly, PTPN2
inhibition unmasked the proapoptotic effect of IFN-
alone in both INS-1E and primary -cells, while it failed to
augment palmitate- or CPA-induced -cell death. Taken
together, these observations indicate two interesting as-
pects that require additional investigation: 1) The crucial
negative feedback of PTPN2 on the STAT1 signaling
pathway suggests that PTPN2 is part of the “defense
mechanisms” triggered by -cells in response to cytokines.
It remains to be clariﬁed why this and other defense
mechanisms (24) are not sufﬁcient to protect -cells
against apoptosis. 2) IFN- alone induces STAT1 activa-
tion, but this only leads to apoptosis when PTPN2 activa-
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DIABETES, VOL. 58, JUNE 2009 1287tion is prevented. This suggests that STAT1 must cross a
“nuclear activation threshold” before becoming proapop-
totic to -cells. It remains to be clariﬁed whether this
threshold depends on the intensity/length and/or periodic-
ity of STAT1 activation, as previously suggested for nu-
clear factor B (33).
The exacerbation of apoptosis in -cells with de-
creased PTPN2 expression is independent of augmented
NO production. This contrasts with observations report-
ing that PTPN2-deﬁcient macrophages produce higher
amounts of nitric oxide under inﬂammatory condi-
tions (40,46), highlighting the differential regulation of
inﬂammation-associated genes in cells from different
backgrounds.
As discussed above, the transcription factor STAT1 has
a major role in cytokine-induced -cell apoptosis in vitro
(18) and in vivo (27). It is thus conceivable that a geneti-
cally determined modiﬁcation in the expression and/or the
function of PTPN2 may sensitize -cells to IFN-/STAT1–
driven proapoptotic signaling, amplifying -cell loss under
inﬂammatory conditions, and in some cases, contributing
to diabetes. The potential effect of the transient hyper-
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remains to be clariﬁed. STAT3 has been reported to be
dispensable for -cell development and function (47), but
it is generally associated with increased survival of tu-
moral cells (48), whereas the insulin receptor may exert
positive feedback on -cell function and survival (20).
Over the past few years, several new candidate genes
have been identiﬁed in human type 1 diabetes. Most of
these genes are expressed in the immune system, includ-
ing major histocompatibility complex (e.g., HLA-DRB1),
CTLA4, IL-2R (CD25), IFIH1 (MDA5), and several protein
tyrosine phosphatases, namely PTPN22, PTPN11, and the
recently reported PTPN2 (3,49). Modiﬁed function or
regulation of these genes could contribute to the develop-
ment of an autoimmune response. Thus, nonsynonymous
single-nucleotide polymorphisms (SNPs) in PTPN22 (hu-
man LYP) have been associated with type 1 diabetes and
other autoimmune processes, probably secondary to de-
fective deletion of autoreactive T-cells during thymic
selection (39). The fact that PTPN22 is not expressed in
-cells (present data) reinforces the likelihood that this is
solely due to effects on the immune system. PTPN2-null
mice present severe abnormalities in the immune system,
resulting in a systemic inﬂammatory disease and wide-
spread tissue inﬁltration by mononuclear cells (13,46,50).
Moreover, the PTPN2 gene is associated with several
other autoimmune disorders besides type 1 diabetes, in-
cluding Crohn’s disease, ulcerative colitis, and rheumatoid
arthritis (49,51,52). It is currently unknown whether the
SNPs identiﬁed in the PTPN2 gene on chromosome 18p11
will lead to a gain or a loss of function of the protein.
PTPN2 overexpression in other cell types has been shown
to induce a p53- and caspase 1–dependent apoptosis (53),
whereas suppression of PTPN2 sensitize -cells to cyto-
kine-induced apoptosis (present data). In experiments on
INS-1E cells, we observed that DNA vector–based overex-
pression of PTPN2 induced 30–50% of apoptosis 36 h after
transfection, whereas there was 8% apoptotic cells in
control-transfected cells (data not shown). These prelim-
inary results require experimental conﬁrmation in primary
rat and human -cells using adenoviral vectors to overex-
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regulated to avoid deleterious effects.
Pancreatic -cells themselves may play an active role in
the pathogenesis of type 1 diabetes (21), and at least three
of the type 1 diabetes–associated genes are expressed in
-cells, namely insulin, IFIH1 (MDA5) (6,54), and PTPN2
(present study). -Cells have been shown to participate
actively in the recruitment and activation of the immune
system by secreting various chemokines and cytokines
under inﬂammatory conditions (18,21,55) and by providing
“danger signals” to the immune system during apoptosis,
especially in the context of local inﬂammation (56). We
presently demonstrate that changes in PTPN2 function in
-cells sensitize these cells to surrounding proapoptotic
inﬂammatory signals (e.g., cytokines), potentially amplify-
ing -cell loss and insulitis. This suggests that PTPN2, a
type 1 diabetes–associated gene, may modulate -cell
apoptosis in early type 1 diabetes independently of its
potential effects on the immune system.
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